Shots:

• The P-III DISCOVER 1 & 2 studies involves assessing of Tremfya (q4w/q8w- SC) vs PBO in 381 & 739 patients with active psoriatic arthritis including those previously treated with biologic anti-TNF alpha agent respectively
• Collective Results: @24wks. met its 1EPs of ACR20 (59%/52% & 64% vs 22% & 33%); patients with ≥3BSA affected with psoriasis and IGA score of ≥2 at baseline (75%/57% & 69%/71% vs 15% & 19%); showed reduction in radiographic damage progression
• Tremfya is a mAb targeting p19 subunit of IL-23 and is an approved therapy in the US- Canada- Japan & EU for moderate to severe plaque psoriasis. The sBLA submission to the US FDA on Sept 13- 2019 & EMA’s validation on Oct 11- 2019 is based on the results of P-III DISCOVERY program

Click here to­ read full press release/ article 

Ref: PRNewswire | Image: Janssen